59.02
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
How many analysts rate Halozyme Therapeutics Inc. as a “Buy”Track top-performing stocks effortlessly - jammulinksnews.com
What analysts say about Halozyme Therapeutics Inc. stockDiscover stock picks with superior returns - jammulinksnews.com
What catalysts could drive Halozyme Therapeutics Inc. stock higher in 2025Unmatched profit potential - jammulinksnews.com
Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN
Halozyme Therapeutics Insider Lowered Holding By 38% During Last Year - 富途牛牛
Morgan Stanley Maintains a Hold on Halozyme Therapeutics (HALO) With a $62 PT - MSN
How Halozyme Therapeutics Inc. stock performs during market volatilitySmart Money Tracking Signal Generator Activated - metal.it
Short Interest Drops in Halozyme Therapeutics Inc. After RallyOversold Recovery Opportunity Stocks Attract Buyers - metal.it
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Halozyme Therapeutics Inc. Outperforms Peers on Volume MetricsPrice Action Based Buy Opportunity List Published - metal.it
Why Halozyme Therapeutics Inc. stock attracts strong analyst attentionProfit Target Stock Opportunity Monitor Activated - metal.it
How Resilient Is Halozyme Therapeutics Inc. Stock During Economic DownturnsMarket Entry and Exit Point Tips From Traders - metal.it
Published on: 2025-07-28 01:53:45 - jammulinksnews.com
Does Halozyme Therapeutics Inc. stock perform well during market downturnsBuild a strong portfolio for growth and safety - jammulinksnews.com
What is Halozyme Therapeutics Inc. company’s growth strategyOutstanding capital returns - jammulinksnews.com
Halozyme’s Promising Cancer Study: A Potential Game-Changer in Oncology - TipRanks
Should I buy Halozyme Therapeutics Inc. stock before earningsRecord-setting profit potential - jammulinksnews.com
What risks could impact Halozyme Therapeutics Inc. stock performanceConsistently superior profits - jammulinksnews.com
38% Of This Halozyme Therapeutics Insider's Holdings Were Sold - simplywall.st
Is Halozyme Therapeutics Inc. stock overhyped or has real potentialBreakout profit opportunities - jammulinksnews.com
Halozyme to Report Second Quarter 2025 Financial and Operating Results - Eastern Progress
BlackRock, Inc. Adjusts Holdings in Halozyme Therapeutics Inc. - GuruFocus
Halozyme Therapeutics Inc. Stock Analysis and ForecastExceptional profit margins - Autocar Professional
Halozyme Therapeutics Says Myeloma Drug With Enhanze Delivery Technology Gets EU Approval - 富途牛牛
Is Halozyme Therapeutics Inc. a good long term investmentFree Risk Assessment Services - jammulinksnews.com
J&J Darzalex injectable cleared in EU for smouldering MM (JNJ) - Seeking Alpha
Halozyme says EU approves new indication for Janssen’s Darzalex Faspro - TipRanks
Breakthrough: EU Approves DARZALEX Faspro as First-Ever Treatment for Early-Stage Multiple Myeloma - Stock Titan
What drives Halozyme Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock - Yahoo Finance
Halozyme to Present Q2 2025 Financial Results After Market Close on August 5 - Stock Titan
Halozyme Stock Maintains Hold Rating Amid CMS Pricing Uncertainty and Regulatory Concerns. - AInvest
자본화:
|
볼륨(24시간):